MedTrace Logo

Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy

NCT06631352 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-10-08

No results posted yet for this study

Summary

1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure.
2. Hepatopancreatoduodenectomy(HPD) has been considered a surgical option for patients with extensive bile duct or gallbladder cancer to achieve an R0 resection.
3. The associated high morbidity and mortality rates have prevented HPD from becoming a standard surgical procedure worldwide.
4. Over the past few decades, the understanding of the bile duct anatomy has significantly improved, and many methods have been developed to assess liver function and future remnant liver volume.
5. We aimed to evaluate the short- and long-term outcomes of HPD and to assess risk factors associated with survival, early recurrence, and major complications to better evaluate the potential of the procedure as a standard treatment.

Conditions

  • Hepatopancreaticobiliary (HPB) Malignancy
  • Gall Bladder Cancer
  • Bile Duct Cancer
  • Pancreatoduodenectomy
  • Hepatectomy

Interventions

OTHER

Hepatopancreatoduodenectomy

Pancreatoduodenectomy with liver resection

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-01
Primary Completion
2023-12-31
Completion
2024-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06631352 on ClinicalTrials.gov